NCT07652736 A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
| NCT ID | NCT07652736 |
| Status | Recruiting |
| Phase | — |
| Sponsor | BeOne Medicines |
| Condition | Advanced Non-Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 440 participants |
| Start Date | 2026-06-05 |
| Primary Completion | 2027-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 440 participants in total. It began in 2026-06-05 with a primary completion date of 2027-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
Eligibility Criteria
Inclusion Criteria: * Participants are eligible to be included in the study only if they meet all the following criteria: 1. Participants or their legal representative must sign written inform consent form (ICF) 2. Participants receive tislelizumab as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the SmPC, within the approved indications in the 4 cohorts described. Note: The decision to treat the patient with a tislelizumab-based regimen, as per its authorized indication, must have been made by the treating physician prior to and independent of the patient's consideration for participation in this study. Exclusion Criteria: * Participants are excluded from the study if they meet any of the following criteria: 1. Participants who are unable to understand all implications of study participation. 2. Participants who have contraindications for treatment with tislelizumab in the investigator's opinion or have any contraindication as listed in the SmPC of tislelizumab. 3. Participants who are deemed ineligible according to the investigator's opinion and the SmPC of tislelizumab.
Contact & Investigator
Study Director
STUDY DIRECTOR
BeOne Medicines
Frequently Asked Questions
Who can join the NCT07652736 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Non-Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07652736 currently recruiting?
Yes, NCT07652736 is actively recruiting participants. Contact the research team at clinicaltrials@beonemed.com for enrollment information.
Where is the NCT07652736 trial being conducted?
This trial is being conducted at Segovia, Spain.
Who is sponsoring the NCT07652736 clinical trial?
NCT07652736 is sponsored by BeOne Medicines. The principal investigator is Study Director at BeOne Medicines. The trial plans to enroll 440 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.